| MMM |
Report |
Adjusted organic sales growth |
BEAT |
pred ~3.6% vs. cons 3.15% |
MEDIUM |
| MMM |
Report |
Adjusted operating margin |
IN-LINE |
pred ~24.8% vs. cons 24.65% |
MEDIUM |
| MMM |
Report |
Adjusted EPS |
BEAT |
pred ~$2.30 vs. cons $2.24 |
MEDIUM |
| MMM |
Guide |
FY26 adjusted EPS guidance |
UNCHANGED |
guide ~$8.60 midpoint vs. cons $8.60 (FY26) |
MEDIUM |
| MMM |
Guide |
FY26 adjusted organic sales growth guidance |
UNCHANGED |
guide ~3.0% vs. cons 3.0% (FY26) |
MEDIUM |
| MMM |
Guide |
FY26 adjusted operating-margin expansion guidance |
UNCHANGED |
guide ~75 bps vs. cons 75 bps (FY26) |
MEDIUM |
| MMM |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| MMM |
Return |
5-day cumulative residual |
+0.6% (FADE) |
A modest reported beat—pred ~3.6% organic growth vs. cons 3.15% and pred ~$2.30 EPS vs. cons $2.24—should support an initial positive reaction, but unchanged FY26 guidance at a ~$8.60 midpoint vs. cons $8.60 leaves out-period estimates largely unrevised and limits follow-through. |
MEDIUM |